6E8Q

S. CEREVISIAE CYP51 COMPLEXED WITH Posaconazole


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.2 Å
  • R-Value Free: 0.253 
  • R-Value Work: 0.210 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161.

Monk, B.C.Keniya, M.V.Sabherwal, M.Wilson, R.K.Graham, D.O.Hassan, H.F.Chen, D.Tyndall, J.D.A.

(2019) Antimicrob. Agents Chemother. 63: --

  • DOI: 10.1128/AAC.02114-18

  • PubMed Abstract: 
  • Tetrazole antifungals designed to target fungal lanosterol 14α-demethylase (LDM) appear to be effective against a range of fungal pathogens. In addition, a crystal structure of the catalytic domain of <i>Candida albicans </i> LDM in complex with the ...

    Tetrazole antifungals designed to target fungal lanosterol 14α-demethylase (LDM) appear to be effective against a range of fungal pathogens. In addition, a crystal structure of the catalytic domain of Candida albicans LDM in complex with the tetrazole VT-1161 has been obtained. We have addressed concern about artifacts that might arise from crystallizing VT-1161 with truncated recombinant CYP51s and measured the impact on VT-1161 susceptibility of genotypes known to confer azole resistance. A yeast system was used to overexpress recombinant full-length Saccharomyces cerevisiae LDM with a C-terminal hexahistidine tag (ScLDM6×His) for phenotypic analysis and crystallographic studies with VT-1161 or with the widely used triazole drug posaconazole (PCZ). We determined the effect of characterized mutations in LDM on VT-1161 activity and identified drug efflux pumps from fungi, including key fungal pathogens, that efflux VT-1161. The relevance of these yeast-based observations on drug efflux was verified using clinical isolates of C. albicans and Candida glabrata VT-1161 binding elicits a significant conformational difference between the full-length and truncated enzymes not found when posaconazole is bound. Susceptibility to VT-1161 is reduced by ATP-binding cassette (ABC) and major facilitator superfamily (MFS) drug efflux pumps, the overexpression of LDM, and mutations within the drug binding pocket of LDM that affect interaction with the tertiary alcohol of the drug.


    Organizational Affiliation

    School of Pharmacy, University of Otago, Dunedin, New Zealand.,Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand.,Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand brian.monk@otago.ac.nz.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Lanosterol 14-alpha demethylase
A
539Saccharomyces cerevisiae (strain YJM789)Mutation(s): 0 
Gene Names: ERG11
Find proteins for A6ZSR0 (Saccharomyces cerevisiae (strain YJM789))
Go to UniProtKB:  A6ZSR0
Small Molecules
Ligands 4 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
X2N
Query on X2N

Download SDF File 
Download CCD File 
A
POSACONAZOLE
C37 H42 F2 N8 O4
RAGOYPUPXAKGKH-XAKZXMRKSA-N
 Ligand Interaction
HEM
Query on HEM

Download SDF File 
Download CCD File 
A
PROTOPORPHYRIN IX CONTAINING FE
HEME
C34 H32 Fe N4 O4
KABFMIBPWCXCRK-RGGAHWMASA-L
 Ligand Interaction
LMT
Query on LMT

Download SDF File 
Download CCD File 
A
DODECYL-BETA-D-MALTOSIDE
C24 H46 O11
NLEBIOOXCVAHBD-QKMCSOCLSA-N
 Ligand Interaction
1PE
Query on 1PE

Download SDF File 
Download CCD File 
A
PENTAETHYLENE GLYCOL
PEG400
C10 H22 O6
JLFNLZLINWHATN-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.2 Å
  • R-Value Free: 0.253 
  • R-Value Work: 0.210 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 77.350α = 90.00
b = 66.560β = 98.47
c = 80.770γ = 90.00
Software Package:
Software NamePurpose
MOSFLMdata reduction
Aimlessdata scaling
PHASERphasing
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Health Research CouncilNew Zealand--

Revision History 

  • Version 1.0: 2018-09-05
    Type: Initial release
  • Version 1.1: 2019-03-20
    Type: Data collection, Database references